The biologics currently used in IBD treatment abroad are divided into two categories, namely tumor necrosis factor alpha (TNF-α) monoclonal antibodies and adhesion molecule inhibitors. 1, tumor necrosis factor alpha (TNF-α) monoclonal antibodies. These biologics include infliximab (IFX), adalimumab and certolizumabpegol, of which IFX is the most prominent. IFX was administered at 5-10 mg/kg intravenously at weeks 0, 2, 6, and every 8 weeks thereafter. The latter two are better tolerated by humans. 2. Adhesion molecule inhibitor – Natalizumab. The use of natalizumab is strictly limited because of its non-selective effect on integrin α4β1/MabACM-1, which may cause progressive multifocal leukoencephalopathy. natalizumab should be used in IBD patients only when anti-TNF-α agents are ineffective and after rigorous screening.